Live
FierceBiotechAstellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 yearsFierceBiotechAmplifon to build vertical hearing aid player with €2.3B GN acquisitionFierceBiotechIdorsia shares sink after CEO's abrupt departureFierceBiotechDespite boosted funding, NIH still slow to award grants: analysisBioPharma DiveStructure’s GLP-1 pill shows ‘best-in-class’ potential in obesity trialBioWorldPrecision psychiatry beyond, or before, biomarkersBioWorldBiggest gainers and losers for March 9-13, 2026Endpoints NewsCytomX reports ADC data in late-line colorectal cancer; FDA OKs Cosentyx label expansionBioPharma DiveSarepta tests new Elevidys safeguards; Sana advances diabetes cell therapyEndpoints NewsNadia Care raises $12M to grow Medicaid maternal careBioWorldCD73-targeting immunoconjugates disclosed in Eisai patentBioWorldKyron-Servier deal focused on programmable glycoprotein platform
FierceBiotech Mar 16, 2026

Astellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 years

Astellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 years

Original
Body unavailable. Use the original source.

Directory

59 All